Merck's cholesterol pill gets US FDA approval

Merck said the U.S. FDA approved its cholesterol pill—the first of its kind—strengthening the company’s strategy to diversify beyond its blockbuster cancer therapy Keytruda. The approval is a major regulatory milestone that should improve growth optionality and support investor confidence in Merck’s pipeline.

Analysis

Merck said the U.S. FDA approved its cholesterol pill—the first of its kind—strengthening the company’s strategy to diversify beyond its blockbuster cancer therapy Keytruda. The approval is a major regulatory milestone that should improve growth optionality and support investor confidence in Merck’s pipeline.